Acrivon Therapeutics (ACRV) Competitors $2.04 +0.12 (+6.25%) Closing price 04:00 PM EasternExtended Trading$2.03 -0.01 (-0.54%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRV vs. FHTX, TRDA, CLLS, GNLX, GNFT, TARA, ZURA, MDWD, PYXS, and EPRXShould you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Foghorn Therapeutics (FHTX), Entrada Therapeutics (TRDA), Cellectis (CLLS), Genelux (GNLX), GENFIT (GNFT), Protara Therapeutics (TARA), Zura Bio (ZURA), MediWound (MDWD), Pyxis Oncology (PYXS), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry. Acrivon Therapeutics vs. Its Competitors Foghorn Therapeutics Entrada Therapeutics Cellectis Genelux GENFIT Protara Therapeutics Zura Bio MediWound Pyxis Oncology Eupraxia Pharmaceuticals Foghorn Therapeutics (NASDAQ:FHTX) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations. Do insiders & institutionals have more ownership in FHTX or ACRV? 61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 7.6% of Foghorn Therapeutics shares are owned by company insiders. Comparatively, 11.9% of Acrivon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is FHTX or ACRV more profitable? Acrivon Therapeutics has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -311.90%. Foghorn Therapeutics' return on equity of 0.00% beat Acrivon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Foghorn Therapeutics-311.90% N/A -28.00% Acrivon Therapeutics N/A -50.78%-46.08% Do analysts rate FHTX or ACRV? Foghorn Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 170.27%. Acrivon Therapeutics has a consensus target price of $15.00, indicating a potential upside of 635.29%. Given Acrivon Therapeutics' higher probable upside, analysts plainly believe Acrivon Therapeutics is more favorable than Foghorn Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Foghorn Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.00Acrivon Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has more volatility & risk, FHTX or ACRV? Foghorn Therapeutics has a beta of 3.03, indicating that its stock price is 203% more volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Which has higher earnings and valuation, FHTX or ACRV? Acrivon Therapeutics has lower revenue, but higher earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFoghorn Therapeutics$22.60M10.18-$86.62M-$1.19-3.42Acrivon TherapeuticsN/AN/A-$80.56M-$2.25-0.91 Does the media favor FHTX or ACRV? In the previous week, Foghorn Therapeutics had 3 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 3 mentions for Foghorn Therapeutics and 0 mentions for Acrivon Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.05 beat Acrivon Therapeutics' score of 0.00 indicating that Foghorn Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Foghorn Therapeutics Neutral Acrivon Therapeutics Neutral SummaryFoghorn Therapeutics beats Acrivon Therapeutics on 9 of the 16 factors compared between the two stocks. Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRV vs. The Competition Export to ExcelMetricAcrivon TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.17M$2.62B$6.11B$10.62BDividend YieldN/A57.79%5.72%4.85%P/E Ratio-0.9123.5929.2227.30Price / SalesN/A587.20491.48184.03Price / CashN/A27.2425.8230.35Price / Book0.365.4112.476.65Net Income-$80.56M$33.06M$3.32B$276.14M7 Day Performance17.24%1.33%1.87%0.01%1 Month Performance25.15%10.15%8.40%3.60%1 Year Performance-74.66%-2.20%63.49%32.76% Acrivon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRVAcrivon Therapeutics2.5958 of 5 stars$2.04+6.3%$15.00+635.3%-76.7%$64.17MN/A-0.9158Positive NewsFHTXFoghorn Therapeutics2.5433 of 5 stars$4.04+1.3%$11.00+172.3%-47.3%$225.55M$22.60M-3.39120Gap UpTRDAEntrada Therapeutics2.9027 of 5 stars$6.25+6.5%$25.67+310.7%-64.2%$223.28M$79.48M-3.51110CLLSCellectis2.1789 of 5 stars$3.95-0.8%$6.00+51.9%+107.9%$221.22M$49.22M-4.82290Analyst ForecastGap DownGNLXGenelux1.0966 of 5 stars$6.51+13.8%$20.33+212.3%+136.7%$216.06MN/A-7.5710News CoverageAnalyst ForecastGap UpHigh Trading VolumeGNFTGENFIT1.8155 of 5 stars$4.08-3.8%$7.00+71.6%-31.3%$212.01M$76.77M0.00120Positive NewsTARAProtara Therapeutics1.7592 of 5 stars$5.56+1.3%$19.60+252.5%+191.1%$211.81MN/A-3.4330ZURAZura Bio3.0393 of 5 stars$3.37+5.0%$11.60+244.2%-31.5%$208.71MN/A-4.813Short Interest ↑MDWDMediWound1.8959 of 5 stars$19.69+4.7%$32.25+63.8%+12.0%$208.38M$19.86M-7.4680PYXSPyxis Oncology2.8579 of 5 stars$3.58+6.5%$7.75+116.5%-4.5%$208.38M$2.82M-2.2460EPRXEupraxia Pharmaceuticals2.6317 of 5 stars$5.88+1.7%$11.00+87.1%+134.3%$207.85MN/A-6.9229Short Interest ↑ Related Companies and Tools Related Companies Foghorn Therapeutics Competitors Entrada Therapeutics Competitors Cellectis Competitors Genelux Competitors GENFIT Competitors Protara Therapeutics Competitors Zura Bio Competitors MediWound Competitors Pyxis Oncology Competitors Eupraxia Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRV) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
